Biotech Values

[DewDiligence]

AAVL gives up on existing AMD program:

http://finance.yahoo.com/news/avalanche-biotechnologies-inc-reports-second-200500978.html

…after further analyses of results from a previously reported Phase 2a trial of AVA-101 for the potential treatment of wet age-related macular degeneration (wet AMD), it will not initiate a Phase 2b clinical trial in the second half of 2015.

Instead, Avalanche will conduct additional preclinical studies to investigate optimal dose and delivery of AVA-101 and AVA-201 versus standard of care anti-VEGF protein therapy to select the best gene therapy product candidate for wet AMD to advance back into the clinic.

Don’t hold your breath for additional news on this program; the above sounds like a longwinded way of dancing around the reality that the program failed and the company is moving on.